间充质基质细胞治疗的不良事件、副作用和并发症。

Q1 Biochemistry, Genetics and Molecular Biology
Stem cell investigation Pub Date : 2022-11-08 eCollection Date: 2022-01-01 DOI:10.21037/sci-2022-025
Denis S Baranovskii, Ilya D Klabukov, Nadezhda V Arguchinskaya, Anna O Yakimova, Anastas A Kisel, Elena M Yatsenko, Sergei A Ivanov, Peter V Shegay, Andrey D Kaprin
{"title":"间充质基质细胞治疗的不良事件、副作用和并发症。","authors":"Denis S Baranovskii,&nbsp;Ilya D Klabukov,&nbsp;Nadezhda V Arguchinskaya,&nbsp;Anna O Yakimova,&nbsp;Anastas A Kisel,&nbsp;Elena M Yatsenko,&nbsp;Sergei A Ivanov,&nbsp;Peter V Shegay,&nbsp;Andrey D Kaprin","doi":"10.21037/sci-2022-025","DOIUrl":null,"url":null,"abstract":"<p><p>Numerous clinical studies have shown a wide clinical potential of mesenchymal stromal cells (MSCs) application. However, recent experience has accumulated numerous reports of adverse events and side effects associated with MSCs therapy. Furthermore, the strategies and methods of MSCs therapy did not change significantly in recent decades despite the clinical impact and awareness of potential complications. An extended understanding of limitations could lead to a wider clinical implementation of safe cell therapies and avoid harmful approaches. Therefore, our objective was to summarize the possible negative effects observed during MSCs-based therapies. We were also aimed to discuss the risks caused by weaknesses in cell processing, including isolation, culturing, and storage. Cell processing and cell culture could dramatically influence cell population profile, change protein expression and cell differentiation paving the way for future negative effects. Long-term cell culture led to accumulation of chromosomal abnormalities. Overdosed antibiotics in culture media enhanced the risk of mycoplasma contamination. Clinical trials reported thromboembolism and fibrosis as the most common adverse events of MSCs therapy. Their delayed manifestation generally depends on the patient's individual phenotype and requires specific awareness during the clinical trials with obligatory inclusion in the patient' informed consents. Finally we prepared the safety checklist, recommended for clinical specialists before administration or planning of MSCs therapy.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/a8/sci-09-2022-025.PMC9659480.pdf","citationCount":"32","resultStr":"{\"title\":\"Adverse events, side effects and complications in mesenchymal stromal cell-based therapies.\",\"authors\":\"Denis S Baranovskii,&nbsp;Ilya D Klabukov,&nbsp;Nadezhda V Arguchinskaya,&nbsp;Anna O Yakimova,&nbsp;Anastas A Kisel,&nbsp;Elena M Yatsenko,&nbsp;Sergei A Ivanov,&nbsp;Peter V Shegay,&nbsp;Andrey D Kaprin\",\"doi\":\"10.21037/sci-2022-025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Numerous clinical studies have shown a wide clinical potential of mesenchymal stromal cells (MSCs) application. However, recent experience has accumulated numerous reports of adverse events and side effects associated with MSCs therapy. Furthermore, the strategies and methods of MSCs therapy did not change significantly in recent decades despite the clinical impact and awareness of potential complications. An extended understanding of limitations could lead to a wider clinical implementation of safe cell therapies and avoid harmful approaches. Therefore, our objective was to summarize the possible negative effects observed during MSCs-based therapies. We were also aimed to discuss the risks caused by weaknesses in cell processing, including isolation, culturing, and storage. Cell processing and cell culture could dramatically influence cell population profile, change protein expression and cell differentiation paving the way for future negative effects. Long-term cell culture led to accumulation of chromosomal abnormalities. Overdosed antibiotics in culture media enhanced the risk of mycoplasma contamination. Clinical trials reported thromboembolism and fibrosis as the most common adverse events of MSCs therapy. Their delayed manifestation generally depends on the patient's individual phenotype and requires specific awareness during the clinical trials with obligatory inclusion in the patient' informed consents. Finally we prepared the safety checklist, recommended for clinical specialists before administration or planning of MSCs therapy.</p>\",\"PeriodicalId\":21938,\"journal\":{\"name\":\"Stem cell investigation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/a8/sci-09-2022-025.PMC9659480.pdf\",\"citationCount\":\"32\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stem cell investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/sci-2022-025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem cell investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/sci-2022-025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 32

摘要

大量临床研究表明间充质间质细胞(MSCs)具有广泛的临床应用潜力。然而,最近的经验积累了大量与MSCs治疗相关的不良事件和副作用的报道。此外,近几十年来,尽管临床影响和潜在并发症的认识,MSCs治疗的策略和方法并未发生显着变化。对局限性的深入了解可以导致更广泛的安全细胞疗法的临床实施,并避免有害的方法。因此,我们的目的是总结在mscs为基础的治疗中观察到的可能的负面影响。我们还旨在讨论细胞处理(包括分离、培养和储存)中的缺陷所造成的风险。细胞加工和细胞培养可以极大地影响细胞种群特征,改变蛋白质表达和细胞分化,为未来的负面影响铺平道路。长期细胞培养导致染色体异常的积累。培养基中抗生素过量增加支原体污染的风险。临床试验报告血栓栓塞和纤维化是MSCs治疗最常见的不良事件。它们的延迟表现通常取决于患者的个体表型,在临床试验期间需要特定的意识,并必须纳入患者的知情同意。最后,我们准备了安全清单,推荐给临床专家在给药或计划MSCs治疗之前。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies.

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies.

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies.

Numerous clinical studies have shown a wide clinical potential of mesenchymal stromal cells (MSCs) application. However, recent experience has accumulated numerous reports of adverse events and side effects associated with MSCs therapy. Furthermore, the strategies and methods of MSCs therapy did not change significantly in recent decades despite the clinical impact and awareness of potential complications. An extended understanding of limitations could lead to a wider clinical implementation of safe cell therapies and avoid harmful approaches. Therefore, our objective was to summarize the possible negative effects observed during MSCs-based therapies. We were also aimed to discuss the risks caused by weaknesses in cell processing, including isolation, culturing, and storage. Cell processing and cell culture could dramatically influence cell population profile, change protein expression and cell differentiation paving the way for future negative effects. Long-term cell culture led to accumulation of chromosomal abnormalities. Overdosed antibiotics in culture media enhanced the risk of mycoplasma contamination. Clinical trials reported thromboembolism and fibrosis as the most common adverse events of MSCs therapy. Their delayed manifestation generally depends on the patient's individual phenotype and requires specific awareness during the clinical trials with obligatory inclusion in the patient' informed consents. Finally we prepared the safety checklist, recommended for clinical specialists before administration or planning of MSCs therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Stem cell investigation
Stem cell investigation Biochemistry, Genetics and Molecular Biology-Developmental Biology
CiteScore
5.80
自引率
0.00%
发文量
9
期刊介绍: The Stem Cell Investigation (SCI; Stem Cell Investig; Online ISSN: 2313-0792) is a free access, peer-reviewed online journal covering basic, translational, and clinical research on all aspects of stem cells. It publishes original research articles and reviews on embryonic stem cells, induced pluripotent stem cells, adult tissue-specific stem/progenitor cells, cancer stem like cells, stem cell niche, stem cell technology, stem cell based drug discovery, and regenerative medicine. Stem Cell Investigation is indexed in PubMed/PMC since April, 2016.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信